Drug intelligence / Profile preview

S-OIV H1N1 vaccine

Development stage: Unknown
Lead developer: The University of Hong Kong
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal, Intramuscular

Overview

The S-OIV H1N1 vaccine refers to a monovalent influenza vaccine targeting the 2009 pandemic swine-origin influenza A (H1N1) virus. In studies conducted by The University of Hong Kong, this vaccine was evaluated for dose-sparing efficacy using intradermal delivery via the MicronJet600 microneedle device. The research aimed to demonstrate that a reduced dose (20% of standard) delivered intradermally could elicit an immune response non-inferior to the standard intramuscular dose, thereby potentially increasing vaccine availability during pandemic shortages.

Other names: Swine-origin influenza virus H1N1 vaccinePandemic H1N1 2009 vaccineH1N1 influenza vaccineH-1N1 influenza vaccineH 1N1 influenza vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on S-OIV H1N1 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-OIV H1N1 vaccine.

Explore the full profile